Compare Dominion Energy Inc (D) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Merck & Co., Inc. — how do they compare? Dominion Energy Inc trades at $61.75 (market cap $54.12B), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 6.5× Dominion Energy Inc's market cap, and Dominion Energy Inc pays the higher dividend (4.34%). Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Merck & Co., Inc. for 98 Days on average.
| D | MRK | |
|---|---|---|
Market Cap | $54.12B | $352.29B |
Volume | 4,249,753 | 6,348,796 |
Sector | Utilities | Health |
52-Week High | $71.67 | $156.43 |
52-Week Low | $57.08 | $82.49 |
Typical Hold Time | 76 Days | 98 Days |
Enterprise Value | $108.24B | $399.05B |
Dividend Yield | 4.34% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.75, down 0.4% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 EPS of $0.79 versus $0.681 expected, continuing a pattern of exceeding expectations. Fundamentals show improving revenue growth to $16.51B in 2025 and net income margin expansion to 13.99%, though cash flow trends show significant capital investments. The pending merger with NextEra Energy dominates recent news coverage, with regulators reviewing a proposed $1 billion annual Virginia supplier program.
Dominion Energy presents a mixed investment case with solid fundamental performance offset by technical weakness and merger execution risks. The stock trades below analyst consensus target of $71.56, offering potential upside if the NextEra merger proceeds smoothly. Key risks include regulatory approval uncertainty, high capital expenditure requirements, and interest rate sensitivity given the company's substantial debt load of $37.31B long-term.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
